The recent discovery of the aberrant expression of DDX3Y compensating the loss of DDX3X function in tumors with c-MYC activation has opened a new area for developing new therapeutic strategies for B cell lymphomas. The gene discussed is DDX3Y; the disease is B-cell non-Hodgkin lymphoma.